Sagimet Biosciences Inc.

What they do

Sagimet develops fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways driven by palmitate overproduction. Its lead candidate, denifanstat, is an oral once-daily selective FASN inhibitor in development for moderate to severe acne, MASH and select cancers; a second FASN inhibitor, TVB-3567, is in a first-in-human Phase 1 trial for acne. The company has no product revenue and funds operations from equity financings; partner Ascletis BioScience conducts denifanstat acne development in China.

Revenue drivers

• Denifanstat in acne (U.S.) — Primary near-term value driver: registrational Phase 3 in moderate to severe acne planned for the second half of 2026, with no revenue until approval and launch.
• Denifanstat in China acne (Ascletis) — Ascletis, Sagimet's license partner, won a Phase 3 in moderate to severe acne and had an NDA accepted by China's NMPA in December 2025; any royalties or milestones are not quantified in the excerpts.
• Denifanstat in MASH and MASH combination — Phase 2b FASCINATE-2 met primary and multiple secondary endpoints in 168 biopsy-confirmed F2/F3 MASH patients; a denifanstat plus resmetirom combination is being studied for F4 cirrhotic MASH.
• TVB-3567 and topical FASN inhibitor — Earlier-stage acne programs: TVB-3567 is in an ongoing Phase 1 with a planned Phase 2 before end-2026, and a topical FASN formulation is also planned. All are pre-revenue.

Recent performance

Sagimet reported a net loss of $14.0 million for the three months ended June 30, 2026, and $24.6 million for the six months, with R&D expense of $11.5 million and $18.5 million for those periods. G&A was $4.3 million for the quarter and $9.0 million for the six months. Cash, cash equivalents and marketable securities were $257.6 million at June 30, 2026, and total assets were $263.4 million against $7.3 million of liabilities and $256.2 million of shareholder equity. Annual net losses have widened from $27.9 million in 2023 to $45.6 million in 2024 and $51.0 million in 2025, with operating cash use of $45.6 million in 2025. The only revenue in the XBRL data is $2.0 million in 2023, with no revenue reported in 2024 or 2025.

Strategy

In April 2026 Sagimet announced a strategic decision to advance denifanstat in moderate to severe acne for the U.S., prioritizing dermatology in its capital allocation. It completed an underwritten equity financing in April 2026 for $175.0 million in gross proceeds and said the resulting $257.6 million cash position funds operations through 2028, including the Phase 3 acne data readout and NDA submission. Management plans a registrational Phase 3 in U.S. moderate to severe acne in the second half of 2026, a Phase 2 for TVB-3567 before end-2026 subject to regulatory consultation, and development of a topical FASN inhibitor. The company also continues MASH work, including combination therapy with resmetirom, and was added to the Russell 3000 and Russell 2000 indices effective June 29, 2026.

Risks

• No approved products or revenue — Sagimet is clinical-stage and has generated no revenue since 2023, so results depend entirely on clinical and regulatory success of denifanstat and TVB-3567.
• Trial timing and outcome — The U.S. Phase 3 acne trial is only planned for the second half of 2026; initiation, enrollment and readout could slip or the trial could fail to replicate the Ascletis Phase 3 results.
• Partner-dependent China data — Key denifanstat acne efficacy and safety data come from Ascletis-conducted trials in China, so U.S. outcomes and NMPA review are outside Sagimet's direct control.
• Tolerability and discontinuation — In FASCINATE-2, treatment-emergent adverse events led to discontinuation in 19.6% of denifanstat patients versus 5.4% on placebo, the most common being eye, gastrointestinal, and skin/subcutaneous disorders.

Outlook

Management states it will advance denifanstat into a registrational Phase 3 clinical trial in moderate to severe acne in the U.S. in the second half of 2026 and, subject to regulatory consultation, start a Phase 2 of TVB-3567 in acne before the end of 2026. It says the April 2026 financing funds current operations through 2028, including the Phase 3 data readout and an NDA submission. Sagimet also plans to develop a topical FASN inhibitor for acne.